Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.93 |
| ▸ | PGR | P06401 | 7/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.93 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.93 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | IL5 | P05113 | 1/20 | 0.93 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.93 |
| ▸ | AR | P10275 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | MMP9 | P14780 | 1/20 | 0.93 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.93 |
| ▸ | THPO | P40225 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL5396843 | 0.96 | NR3C1 (0.94) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL6059521 | 0.96 | NR3C1 (0.94) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL4448854 | 0.96 | NR3C1 (0.97) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL16731476 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL14452945 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13871728 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL1130417 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13928654 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12396756 | 0.96 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038660-B1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORP (US) | 2020-12-23 | — | — | EP | claimed |
| CN-105324132-B | Glycosaminoglycan compounds, pharmaceutical compositions and uses thereof | 爱禾公司 | 2020-07-21 | — | — | CN | claimed |
| WO-2024037644-A1 | PEG-MODIFIED GLUCOCORTICOID MEDICAMENT AND USE THEREOF | 津药生物科技（天津）有限公司 | 2024-02-22 | — | — | WO | disclosed |
| EP-3038660-B1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORP (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-105324132-B | Glycosaminoglycan compounds, pharmaceutical compositions and uses thereof | 爱禾公司 | 2020-07-21 | — | — | CN | disclosed |
| CN-110590971-A | Glycosaminoglycan compounds, pharmaceutical compositions and uses thereof | 爱禾公司 | 2019-12-20 | — | — | CN | disclosed |
| US-20170151266-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DRUG DELIVERY TO THE EYE AND EXTENDED DELIVERY FORMULATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-9562015-B2 | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3038660-A1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | Aihol Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| CN-105324132-A | Glycosaminoglycan compounds, pharmaceutical compositions and uses thereof | AIHOL CORP | 2016-02-10 | — | — | CN | disclosed |
| WO-2015031425-A1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065450-A1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | HOLY STONE HEALTHCARE CO., LTD. (TW) | 2015-03-05 | — | — | US | disclosed |
| US-20140309200-A1 | Methods and Compositions for Enhanced Drug Delivery to the Eye and Extended Delivery Formulations | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| EP-2780009-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DRUG DELIVERY TO THE EYE AND EXTENDED DELIVERY FORMULATIONS | The Regents of the University of Colorado, a body corporate (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074988-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DRUG DELIVERY TO THE EYE AND EXTENDED DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309200-A1 | Methods and Compositions for Enhanced Drug Delivery to the Eye and Extended Delivery Formulations | CRH, PCNP, PRDX1 | NR3C1 27/4885PGR 154/4885CYP3A4 980/4885 |
| US-20170151266-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DRUG DELIVERY TO THE EYE AND EXTENDED DELIVERY FORMULATIONS | CRH, PCNP, PRDX1 | NR3C1 27/4885PGR 154/4885CYP3A4 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.